Case Series Congenital Myasthenic Syndromes: Early to diagnose, early to rise

Pramod Dhonde; Mayura Dhonde

doi:10.15713/ins.bhj.83

Authors

Pramod Dhonde Consultant Neurologist, Dhonde Hospital and Shivansh Neurorehabilitation centre
Mayura Dhonde Consultant Neuroelectrophysiologist, Dhonde Hospital, Nanded

DOI:

https://doi.org/10.15713/ins.bhj.83

Keywords:

Congenital myasthenic syndrome, CHRNE, pyridostigmine

Abstract

Congenital myasthenic syndromes (CMS) are phenotypically heterogeneous disorders with defects at presynaptic, synaptic and postsynaptic level. With the worldwide prevalence of CMS unknown, from India either case reports or hospital based studies ^1-3 give insight into the spectrum of CMS. At present more than 20 genes have been associated with CMS, majority are CHRNE (50%, including both autosomal dominant and recessive), RAPSN (15%-20%), DOK7 (10%-15%), COLQ (10%-15%), GFPT1 (2%).⁴ We are reporting 4 cases of CMS with typical presentation of fatiguable ptosis at early age in all patients and limb girdle weakness in two patients. One presented with history of respiratory arrest after fluoroquinolone use. All of them had positive slow rate repetitive nerve stimulation (RNS). Two patients had pathogenic compound heterozygous and homozygous mutations respectively for CHRNE, one patient had heterozygous mutation for SLC25A1 with uncertain significance with one patient’s report unknown. Two patients (one CHRNE and SLC25A1) responded with pyridostigmine only and two patients responded to pyridostigmine and salbutamol.

References

Girija A, Somanath V, John J, Jose J. Congenital myasthenic syndrome – a report of nineteen cases. Ann Indian Acad Neurol 2001;4:71–6.

Selvam P, Arunachal G, Danda S, Chapla A, Sivadasan A, Alexander M, et al. Congenital myasthenic syndrome : spectrum of mutations in an indian cohort. J Clin Neuromuscul Dis 2018;20:14–27.

Wadwekar V, Nair S, Tandon V, Kuruvilla A, Nair M. Congenital myasthenic syndrome: Ten years clinical experience from a quaternary care south-Indian hospital. J Clin Neurosci 2020 Feb;72:238-243.

Beeson D. Congenital myasthenic syndromes: recent advances. Curr Opin Neurol 2016;29:565-71.

Parr JR, Andrew MJ, Finnis M, Beeson D, Vincent A, Jayawant S. How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Arch Dis Child 2014;99:539–42.

Durmus H, Shen XM, Serdaroglu-Oflazer P, Kara B, Parman-Gulsen Y, Ozdemir C, et al. Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up. Neuromuscul Disord 2018;28:315–22.

Morar B, Gresham D, Angelicheva D, et al. Mutation history of the roma/gypsies. Am J Hum Genet. 2004; 75:596–609.

Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: Pathogenesis, diagnosis,and treatment. Lancet Neurol 2015;14:420–34.